David Alastair Flockhart

David Alastair Flockhart's AcademicInfluence.com Rankings

Medical

#2895

World Rank

#3339

Historical Rank

Pharmacology

#330

World Rank

#381

Historical Rank

medical Degrees

Download Badge

Medical

Why Is David Alastair Flockhart Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Alastair Flockhart's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. (2005) (932)
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism (2002) (907)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. (2003) (837)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. (2005) (769)
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 (2004) (636)
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity (2003) (612)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen (2006) (577)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment (2006) (468)
Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen (2004) (447)
Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1978) (338)
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. (2001) (307)
Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. (2001) (303)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen (2005) (296)
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. (2012) (290)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2007) (286)
Regulatory mechanisms in the control of protein kinases. (1982) (282)
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. (2006) (277)
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. (2010) (231)
Inhibition of IL-12 production by thalidomide. (1997) (229)
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. (1997) (228)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. (2007) (226)
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin (2008) (216)
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. (2010) (199)
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors (2008) (196)
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. (1999) (191)
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. (2011) (183)
The IGNITE network: a model for genomic medicine implementation and research (2015) (180)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A (2001) (174)
The emerging role of cytochrome P450 3A in psychopharmacology. (1995) (171)
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. (2004) (168)
Pharmacogenomics: Challenges and Opportunities (2006) (162)
The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study (1995) (162)
Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells (2006) (160)
Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. (1999) (152)
Greater quinidine‐induced QTc interval prolongation in women (2000) (144)
Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. (1998) (141)
Implications of cytochrome P450 interactions when prescribing medication for hypertension. (2002) (139)
Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study (2010) (129)
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting (2016) (129)
Drug‐metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests (2005) (121)
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition (2012) (120)
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) (1999) (115)
Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. (2002) (115)
Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men (2005) (114)
Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. (2002) (114)
Pharmacokinetic and Pharmacodynamic Consequences of Metabolism‐Based Drug Interactions with Alprazolam, Midazolam, and Triazolam (1999) (113)
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. (2003) (112)
In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. (2000) (112)
Drug Interactions and the Cytochrome P450 System (1995) (112)
Cytochrome P450-mediated drug interactions. (2000) (112)
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients (2010) (112)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. (2008) (110)
The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. (2001) (108)
Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions (2012) (102)
Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study (2008) (99)
Variability of heart rate correction methods for the QT interval. (2003) (97)
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. (2008) (95)
Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. (2002) (95)
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 (2015) (91)
Association Between the CYP3A5 Genotype and Blood Pressure (2005) (91)
PharmGKB summary: tamoxifen pathway, pharmacokinetics (2013) (90)
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. (2012) (90)
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age (2011) (89)
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. (2003) (88)
Clonidine in the Treatment of ADHD: Questions about Safety and Efficacy (1995) (87)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2008) (82)
Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers (2007) (81)
Predicting asparaginase‐associated pancreatitis (2007) (80)
The Star‐Allele Nomenclature: Retooling for Translational Genomics (2007) (80)
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants (2006) (79)
Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. (2009) (77)
Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy (2014) (76)
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. (2000) (76)
Association of polymorphisms of angiogenesis genes with breast cancer (2008) (75)
Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. (2002) (75)
Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. (1998) (74)
Studies on the structure and mechanism of activation of the guanosine 3':5'-monophosphate-dependent protein kinase. (1978) (74)
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. (2010) (73)
Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. (2000) (73)
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. (2004) (72)
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer (2011) (71)
Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (1997) (71)
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. (2010) (71)
In Vitro Cytochrome P450-Mediated Metabolism of Exemestane (2011) (71)
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort (2009) (69)
In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphatase. (1977) (68)
In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4α Expression (2012) (68)
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics (2012) (68)
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. (2014) (68)
Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy (2006) (67)
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. (2012) (67)
Studies on the phosphorylation and dephosphorylation of L-type pyruvate kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. (1980) (66)
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. (2003) (64)
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents (2012) (63)
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
Selection of Drugs to Treat Gastro-Oesophageal Reflux Disease (2000) (63)
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. (1998) (62)
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (2000) (61)
Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. (2011) (60)
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? (2009) (59)
Creating and evaluating genetic tests predictive of drug response (2008) (59)
Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. (2000) (59)
2010 guide to psychiatric drug interactions (2004) (57)
Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype (1996) (56)
Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. (2011) (54)
Modeling hot flushes and quality of life in breast cancer survivors (2011) (54)
Pharmacogenetics in the treatment of breast cancer (2004) (54)
Guide to Psychiatric Drug Interactions (2006) (54)
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. (2012) (52)
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer (2016) (51)
Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. (2001) (51)
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. (2008) (51)
Human sympathetic activation by α2‐adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450–mediated drug metabolism (2004) (50)
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity (2011) (50)
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. (2013) (49)
In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms (2000) (49)
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. (2004) (49)
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer (2013) (49)
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. (2005) (47)
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation (2010) (47)
Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. (2000) (46)
Cytochrome P450 3A pharmacogenetics: the road that needs traveled (2003) (45)
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. (2016) (44)
Visual Hallucination and Tremor Induced by Sertraline and Oxycodone in a Bone Marrow Transplant Patient (2001) (44)
Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? (1996) (43)
An integrated pharmacokinetics ontology and corpus for text mining (2013) (43)
Studies on functional domains of the regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1980) (42)
Effect of cyclic nucleotide analogs on intrachain site I of protein kinase isozymes. (1982) (42)
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 (2014) (41)
ATP analog specificity of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and phosphorylase kinase. (1984) (41)
Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools (2002) (40)
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro (2009) (40)
Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. (2007) (40)
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy (2009) (40)
Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen (2008) (39)
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. (2015) (38)
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole (2015) (37)
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? (2008) (37)
Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6 (2003) (37)
Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data (2015) (36)
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics (2002) (36)
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study (2010) (36)
Impact of the Interaction between 3′-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes (2012) (35)
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity (2009) (35)
Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test (2009) (35)
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer (2011) (35)
Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes (2013) (34)
Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays (2010) (34)
The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates (2005) (34)
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer (2013) (33)
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes (2006) (31)
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. (2015) (30)
Olanzapine-Induced Rhabdomyolysis (2001) (30)
Pharmacogenetic characteristics of the eosinophilia‐myalgia syndrome (1994) (30)
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects (2013) (30)
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes (2014) (29)
Improving the quality of adverse drug reaction reporting by 4th‐year medical students (2003) (29)
Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors (2015) (28)
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. (2013) (27)
Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole (2012) (27)
Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (1998) (27)
Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance (2008) (27)
Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. (2001) (25)
Germline pharmacogenetics of tamoxifen response: have we learned enough? (2007) (25)
Pharmacotherapy and Pregnancy: Highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy (2009) (25)
Formal education about medication errors in internal medicine clerkships. (2001) (25)
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover (2015) (25)
Methadone: A Substrate and Mechanism-Based Inhibitor of CYP19 (Aromatase) (2010) (24)
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy (2009) (24)
The Need for Translational Research on Drug–Drug Interactions (2012) (24)
Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. (2011) (22)
Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers (1999) (22)
Indexing pharmacogenetic knowledge on the World Wide Web. (2003) (22)
Association Between the CYP 3 A 5 Genotype and Blood Pressure (2005) (22)
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics (2016) (22)
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin (2013) (21)
Investigation of the subcellular distribution of cyclic-AMP phosphodiesterase in rat hepatocytes, using a rapid immunological procedure for the isolation of plasma membrane. (1979) (21)
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer (2016) (21)
Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. (2016) (20)
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. (2016) (20)
Drug–drug interaction prediction: a Bayesian meta‐analysis approach (2007) (20)
Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. (2014) (20)
Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed. (2009) (20)
Pharmacogenomically actionable medications in a safety net health care system (2016) (20)
Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia (2004) (20)
C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting (2013) (20)
QT analysis: a complex answer to a ‘simple’ problem (2004) (20)
Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene (2012) (19)
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response (2012) (19)
Pharmacogenetics of Drug Metabolism (2017) (18)
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. (2012) (17)
CYP2D6 genotype and tamoxifen response (2005) (17)
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response (2013) (17)
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent (2013) (17)
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
Inhibition of Cytochrome P450 Enzymes by the E- and Z-Isomers of Norendoxifen (2013) (16)
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy (2015) (16)
Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. (2001) (16)
Enhanced Sensitivity to Drug‐Induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction (2012) (16)
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease (2014) (15)
Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part II (2006) (15)
Creating incentives for genomic research to improve targeting of therapies (2004) (15)
Ticlopidine inhibits phenytoin clearance (1999) (15)
Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. (1997) (15)
Effect of CYP3A inhibition on vesnarinone metabolism in humans * (1998) (14)
Pharmacokinetics of Ibutilide in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction (2008) (14)
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy (2009) (14)
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β. (2016) (14)
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics (2014) (14)
Chapter 12 – PREPARATION OF THE CATALYTIC SUBUNIT OF cAMP-DEPENDENT PROTEIN KINASE1 (1984) (14)
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure (2012) (14)
Tamoxifen Downregulates Ets Oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction (2011) (13)
S‐Mephenytoin hydroxylation phenotypes in a Jordanian population (1995) (13)
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes (2009) (13)
Induction of Testosterone Metabolism by Esomeprazole in aCYP2C19*2 Heterozygote (2004) (13)
CYP2D6 genotyping and the pharmacogenetics of tamoxifen. (2008) (12)
Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. (2016) (12)
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons (2016) (12)
Pharmacotherapy and Pregnancy: Highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy (2009) (12)
Functional characterization of the 5′‐regulatory region of human CYP2C19 (2003) (12)
Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. (2003) (11)
Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype (2002) (11)
Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). (2006) (11)
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. (2013) (11)
Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers (2014) (11)
Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. (2000) (10)
Removal of phosphate from proteins by the reverse reaction. (1983) (10)
Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
Is personalized medicine achievable in obstetrics? (2014) (9)
Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers (2016) (9)
Single Isomer Versus Racemate: Is There a Difference? Clinical Comparisons in Allergy and Gastroenterology (2002) (9)
Steroid Pathway Genes and Neonatal Respiratory Distress After Betamethasone Use in Anticipated Preterm Birth (2016) (9)
Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? (2012) (9)
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer (2017) (9)
Antiestrogen pathway (aromatase inhibitor). (2009) (9)
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel (2015) (9)
Enhancing Race‐Based Prescribing Precision with Pharmacogenomics (2007) (9)
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. (2007) (9)
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors (2017) (8)
Tamoxifen and Its Metabolites Cause Acute Vasorelaxation of Aortic Rings by Inducing Vasodilator Prostanoid Synthesis (2011) (8)
A Mixture Model Approach in Gene–Gene and Gene–Environmental Interactions for Binary Phenotypes (2008) (8)
Discussion: a fresh look at monoamine oxidase inhibitors for depression. (2012) (8)
Pharmacotherapy and Pregnancy (2009) (7)
The IGNITE network: a model for genomic medicine implementation and research (2015) (7)
Reduced Methadone Clearance During Aromatase Inhibition (2012) (7)
In silico and in vitro identification of microRNAs that regulate HNF 4 A expression (2012) (7)
Principles of Pharmacogenetics and Pharmacogenomics: Contributors (2011) (6)
Stereoselective inhibition of CYP2D6 by chlorpheniramine (1995) (6)
The unfinished business of U.S. drug safety regulation. (2006) (6)
A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. (2009) (6)
FDA's draft guidance on laboratory‐developed tests increases clinical and economic risk to adoption of pharmacogenetic testing (2015) (6)
Big Data: Challenges and opportunities for clinical pharmacology (2016) (6)
Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series (2011) (5)
Pharmacogenomics in Pregnancy (2013) (5)
Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements. (1994) (5)
Chapter 21 – Pharmacogenetics of Drug Metabolism (2009) (5)
Abstract S3-02: Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy (2013) (5)
Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride (1999) (5)
Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. (2016) (5)
Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. (2009) (5)
In Vitro Inhibition of Pimozide N-Dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin (2002) (5)
Breast cancer pharmacogenomics: where we are going. (2012) (5)
Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans. (2004) (4)
Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial. (2016) (4)
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. (2013) (4)
Amlodipine – not a significant contributor to clopidogrel non-response? (2013) (4)
The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife. (2004) (4)
Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part I (2006) (4)
Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention (2016) (4)
CALMODULIN AND CALMODULIN-BINDING PROTEINS IN NORMAL AND VIRUS-TRANSFORMED FIBROBLASTS: LEVELS, SUBCELLULAR DISTRIBUTION, AND REGULATION1 (1982) (3)
Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms (2007) (3)
Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
Cytochrome P450 (CYP) 2A6 Genetic Variation Predicts Letrozole Plasma Concentrations in Postmenopausal Women with Breast Cancer. (2009) (3)
One size fits one: pharmacogenetics in gastroenterology. (2014) (3)
A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. (2016) (3)
Faculty Opinions recommendation of Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2008) (3)
CYP 2 B 6 , CYP 3 A 4 , AND CYP 2 C 19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES (2004) (3)
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer – the Development and Validation of New Therapeutics’ (2005) (3)
Erratum: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients (Journal of Clinical Pharmacology (2010) 50: 4 (450-458) DOI: 10.1177/0091270009359182) (2010) (3)
Thalidomide pharmacokinetics do not change with chronic administration (1997) (3)
Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis. (2015) (3)
Estimating a Positive False Discovery Rate for Variable Selection in Pharmacogenetic Studies (2007) (3)
P450 Metabolism in Fibromyalgia (1995) (3)
Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes (2012) (3)
A Penalized Mixture Model Approach in Genotype/Phenotype Association Analysis for Quantitative Phenotypes (2010) (3)
Evaluating drugs after their approval for clinical use. (1994) (2)
Characterization of tamoxifen metabolism to a novel, putative active metabolite (2001) (2)
Working Group on Pharmacogenetic Testing of CYP 2 C 9 , VKORC 1 Alleles for Warfarin Use : (2008) (2)
Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide (2011) (2)
A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. (2009) (2)
In vitro letrozole N‐dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A (2005) (2)
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population. (2009) (2)
Immunological Isolation of Hepatocyte Plasma Membranes (1978) (2)
Abstract P4-02-01: Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study (2010) (2)
Chapter 13 – Clinical Pharmacogenetics (2007) (1)
Estrogen receptor genotype is associated with platelet inhibition after tamoxifen treatment (2006) (1)
Comment on: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Authors' reply (2004) (1)
Abstract 4460: Aromatase inhibition by active tamoxifen metabolites (2011) (1)
Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography. (1998) (1)
The incidence of genetic polymorphisms of CYP 2C in a Korean population (1997) (1)
Mechanism-based inactivation of CYP2C19 and CYP2D6 by tamoxifen (TAM) and its metabolite n-desmethyltamoxifen (NDTAM) (2001) (1)
Abstract P1-08-11: Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy (2013) (1)
An integrated pharmacokinetics ontology and corpus for text mining (2013) (1)
Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN (2004) (1)
Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity (2015) (1)
Effect of Roux-en-Y Gastric Bypass Surgery on the Metabolism of the Orally Administered Medications (2011) (1)
Metabolism of pimozide by CYF3A and CYP2D6 in human liver microsomes (1997) (1)
Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races. (2011) (1)
Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner (2001) (1)
PI‐24 (2006) (1)
Overview of the pharmacokinetics of fluvoxamine. Discussion (1995) (1)
Germline pharmacogenomics as a tool to individualize therapy in breast cancer (2009) (1)
Cloning and sequencing of 5′-regulatory region of CYP2C19 (2001) (1)
Endoxifen has antiestrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. (2004) (1)
Abstract PD10-08: Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121) (2012) (1)
An Update on MAOIs: Dietary Restrictions and Drug Interactions (2012) (1)
Effect of grapefruit juice (GFJ) on the stereo-selective pharmacokinetics (PK) of cisapride (CIS) and cardiac qtc interval in healthy volunteers (2001) (1)
Thiotepa is a specific inhibitor of cytochrome P450 2B6 Implications for cyclophosphamide metabolism (2002) (1)
Interaction of Calmodulin with cAMP Dependent Protein Kinase in Brain (1982) (1)
Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response (2014) (0)
Role of CYP3A4 and CYP2B6 in the in vitro N‐demethylation of meperidine (2004) (0)
CYP genotypes influence the effect of tamoxifen therapy on serum lipids (2004) (0)
Abstract 2451: Increased Myocardial Sensitivity to IKr Inhibition in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction (2009) (0)
In vitro inhibition of tricyclic antidepressants (TCAs) on phenytoin P-hydroxylation: Involvement of CYP2C9 and CYP2C19 (2001) (0)
In vitro metabolism of toborinone by human liver cytochrome P450 isoforms (1998) (0)
Does Roux-en-Y Gastric Bypass Affect the Metabolism of the Orally Administered Medications?: 2010 Presidential Poster: 225 (2010) (0)
S1588 Cirrhotic Patients with TIPS Are At Risk for Medication Induced QT Prolongation (2009) (0)
CYP2D6 poor metabolizers in depressed women of Mexican origin (2004) (0)
First-in-Class Product Seeks To Promote Better Prescribing Habits (2009) (0)
Microarray analysis of drug metabolizing enzyme induction in primary hepatocyte cultures (2001) (0)
In Vitro P 450-Mediated Metabolism of Exemestane (2010) (0)
Abstract 18453: Morbid Obesity and Metabolic Syndrome in Ossabaw Swine Are Associated with Increased Responsiveness of Platelets to Various Agonists (2010) (0)
Effect of selective serotonin reuptake inhibitors (SSRIS) and clonidine on the secondary metabolism of tamoxifen (TAM) by genetically polymorphic CYP2D6 (2001) (0)
Indiana Biobank (IB) (2011) (0)
Breast Cancer Tamoxifen Dose Escalation in Patients With Diminished CYP 2 D 6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (2016) (0)
[Importance of pharmacogenetics in antiretroviral metabolism and drug-transporters]. (2011) (0)
Pharmacogenetic testing ofCYP2C9andVKORC1 alleles for warfarin (2008) (0)
Abstract P5-12-05: CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (2016) (0)
Identification and Characterization of Human Cytochrome P 450 Isoforms Interacting with Pimozide 1 (1998) (0)
Oxandrolone-Warfarin Interactions (2004) (0)
Special Section on Epigenetic Regulation of Drug Metabolizing Enzymes and Transporters Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes s (2013) (0)
Phase I I E valuation o f T halidomide i n P atients W ith Metastatic B reast C ancer (2000) (0)
In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors (SSRIS) antidepressants and azithromycin (2001) (0)
Factor XIII Val 34 Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease (2014) (0)
Oral Session I (OI) Population‐Based Advances in Pharmacotherapy 10:45 am – 12:00 Noon (2014) (0)
2004 GuidetoPsychiatric Drug Interactions (2004) (0)
Editors' report for 2014, November 2014 (2015) (0)
DMD052886 1763..1768 (2013) (0)
INFLUENCE OF PROGESTERONE ADMINISTRATION ON DRUG-INDUCED TORSADES DE POINTES IN AV NODE-ABLATED ISOLATED PERFUSED RABBIT HEARTS (2016) (0)
Tamoxifen Metabolism, SSRIs, and the Cancer Patient (2008) (0)
Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy. (2012) (0)
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure (2012) (0)
The association between CYP3A5 genotype and antihypertensive response (2004) (0)
Principles of Pharmacogenetics and Pharmacogenomics: Introduction (2012) (0)
Effect of Roux-en-Y Gastric Bypass on the Pharmacodynamic Response to Orally Administered Drugs (2011) (0)
Immunological isolation of hepatocyte plasma membranes [proceedings]. (1978) (0)
The Disposition of Reduced Haloperidol and HPP,+ Metabolites of Haloperidol, is Not Influenced by P-Glycoprotein (2006) (0)
Oral Session I (2015) (0)
The association between the CYP3A5 genotype and blood pressure (2004) (0)
Conversion of dimethoxymethyl-diphenylbarbituric acid (DMMDPB) to diphenylbarbituric acid (DPB) in the rat (1996) (0)
Abstract P5-12-06: Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen (2016) (0)
OIV‐B‐3 (2006) (0)
Lack of effect of insulin on guanosine 3':5'-cyclic monophosphate content of insulin-sensitive rat hepatocytes [proceedings]. (1979) (0)
Abstract 1875: Identifying genetic variants contributing to cellular susceptibility to tamoxifen using a genome-wide cell-based model (2012) (0)
Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer (2001) (0)
Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy. (2015) (0)
Presidential Trainee Awards (PT 1–13) (2012) (0)
Abstract 3604: Significant effect of polymorphisms in CYP2D6 and DT-1 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients (2010) (0)
Abstract 18740: Influence of Oral Progesterone Administration on QT Interval Response to Ikr Inhibition (2014) (0)
In vivo and in vitro phosphorylation of rat liver fructose-1 , 6-bisphosphatase ( hexosediphosphatase / protein kinase / gluconeogenic enzyme / cyclic AMP ) (0)
Editors' report, November 2013. (2014) (0)
Omeprazole (OPZ) as a Probe for the CYP2C19 Polymorphism in an African‐American (AA) Population (1996) (0)
Halofantrine Safety, Tolerance and Metabolism Studies. (1997) (0)
In reply [2] (2006) (0)
Germline pharmacogenomics in the treatment of breast cancer (2008) (0)
Phase-I study of hepapoietin on liver function (2000) (0)
Pharmacogenetic determinant of cyclophosphamide therapy in patients with lupus nephritis (2003) (0)
Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes. (2009) (0)
Abstract 4306: Simultaneous Administration of High Dose Atorvastatin and Clopidogrel Loading Doses Does Not Interfere With Platelet Inhibition During Percutaneous Coronary Intervention (2009) (0)
Editors' Report for 2015, December 2015. (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Alastair Flockhart?

David Alastair Flockhart is affiliated with the following schools:

David Alastair Flockhart's Academic­Influence.com Rankings

Why Is David Alastair Flockhart Influential?

David Alastair Flockhart's Published Works

Published Works

What Schools Are Affiliated With David Alastair Flockhart?

David Alastair Flockhart's AcademicInfluence.com Rankings